- Overview
- EIFU & Resources
Facilimix™ Compounding Device is designed to eliminate syringe push/pull motions.
Intuitive to use, as the device mimics syringe motion, it enables to withdraw and inject compound with one finger.
The Facilimix™ Cartridge is a dedicated patented* double seal syringe designed for use with the Facilimix™ Compounding Device.
Compatible with oncology drugs including paclitaxel4,5 the standard luer lock cartridge has a double seal to increase accuracy and avoid leakage.
Facilimix™ in use with BD Texium™
Facilimix™ in use with BD PhaSeal™
Facilimix™ in use with BD PhaSeal™ Optima
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.
*patent number: US 2013/0199668 A1
References
F. Reisz, AC. Gairard-Dory, K. Fonmartin, J. Bourbon, B. Gourieux. Prévention des troubles musculo squelettiques en pharmacotechnie. Groupe d’évalutation de recherche sur la protection en atmosphère contrôlée (GERPAC).
GERPAC . Accessed on May 6, 2018.
The National Institute for Occupational Safety and Health (NIOSH) Safe patient handling and mobility (SPHM).
Safe Patient Handling and Mobility (SPHM) | NIOSH | CDC . Accessed June, 2019.Nancy N. Byl, Mary F. Barbe, Carolyn Byl Dolan, Grant Glass. Repetitive Stress Pathology: Soft Tissue in Pathology and Intervention in Musculoskeletal Rehabilitation. Second Edition 2016, Pages 938-1004.
Dr. Federico Reverberi. Paclitaxel stability in physiologic solution after contact with medical device. August 2016
J. Vignerona et al. SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update. Annales Pharmaceutiques Françaises (2013) 71, 376—389
BD-22023